Sanofi has the perfect gift for investors: Investment in its most promising businesses with plans to keep growing the dividend.
News & Analysis: Synthorx
Sanofi, with sales falling in its older businesses, boosts its higher-growth immuno-oncology business with the $2.5 billion purchase of Synthorx.
Two big deals for cancer drug companies made news today. Merck plans to buy ArQule and Sanofi will pay up to buy Synthorx.
Sanofi and the clinical-stage biotech Synthorx announced a $2.5 billion buyout agreement Monday morning.
Three companies in industries that Wall Street isn't paying enough attention to. Don't miss out, too.